Nkarta Inc. (NKTX)
1.73
-0.02 (-1.14%)
At close: Mar 03, 2025, 12:37 PM
No 1D chart data available
| Bid | 1.72 |
| Market Cap | 122.08M |
| Revenue (ttm) | 10.11M |
| Net Income (ttm) | -106.11M |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -0.95 |
| Forward PE | -1.27 |
| Analyst | Buy |
| Ask | 1.73 |
| Volume | 271,880 |
| Avg. Volume (20D) | 1,470,539 |
| Open | 1.77 |
| Previous Close | 1.75 |
| Day's Range | 1.72 - 1.79 |
| 52-Week Range | 1.70 - 16.24 |
| Beta | 0.85 |
About NKTX
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 159
Stock Exchange NASDAQ
Ticker Symbol NKTX
Website https://www.nkartatx.com
Analyst Forecast
According to 5 analyst ratings, the average rating for NKTX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 824.86% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
6 months ago
+3.22%
Nkarta shares are trading higher after the company...
Unlock content with
Pro Subscription
7 months ago
+13.96%
Nkarta shares are trading higher after the company appointed Nadir Mahmood as President.
